News

Somite Therapeutics Partners with OmniaBio for Cell Therapy

Somite Therapeutics Partners with OmniaBio for Cell Therapy

Collaboration Announcement: Somite Therapeutics and OmniaBio

This partnership aims to advance cell replacement therapy for a serious genetic disorder.

Somite Therapeutics and OmniaBio Inc. have joined forces to enhance the production of cell therapies specifically for Duchenne muscular dystrophy (DMD). Their collaboration is focused on refining the development of SMT-M01, an innovative therapy that has the potential to restore muscle function in individuals affected by this challenging condition.

Professor Peter Zandstra expressed great enthusiasm for this partnership, highlighting its potential to drive long-term advancements not only for this specific program but also for the broader field of cell therapy. He underscored Somite’s pioneering use of artificial intelligence in discovering and optimizing cell therapies, which opens up exciting opportunities to improve both the effectiveness and cost-efficiency of these treatments.

Duchenne muscular dystrophy is a serious genetic disorder that leads to progressive muscle degeneration and currently has no cure. This collaboration aims to combine the expertise of both companies to create an advanced cell replacement therapy that can slow the disease's progression and significantly enhance the quality of life for those diagnosed with DMD.

Dr. Kristy Brown from Somite Therapeutics noted that collaborating with OmniaBio provides invaluable experience in iPSC technology, which is crucial for the efficient advancement of their DMD program. This partnership instills confidence in the development process and ensures regulatory compliance, allowing for the expedited delivery of vital therapies to patients in need.

As part of the collaboration, OmniaBio will oversee several essential processes, including master cell banking, pluripotent stem cell differentiation, and the optimization of harvesting conditions for drug production. This methodical approach is grounded in their extensive experience with induced pluripotent stem cell technology.

Looking forward, Dr. Micha Breakstone, CEO of Somite Therapeutics, mentioned that they expect to enter phase one/two clinical trials within the next eighteen to twenty-four months. He shared his excitement about how this collaboration could transform patient outcomes and further advance the field of stem cell biology.

Mitchel Sivilotti, President and CEO of OmniaBio, also expressed optimism about how their combined efforts could lead to groundbreaking innovations in treatments for DMD patients around the world. He pointed out that their deep knowledge of iPSC technology, along with a growing emphasis on AI-driven innovations, will be crucial in enhancing manufacturing processes and speeding up clinical translation.

About Somite Therapeutics

Recently established, Somite Therapeutics is committed to revolutionizing stem cell biology by integrating artificial intelligence with cell therapy research. Their unique AI-powered platform, known as AlphaStem, aims to create human tissues for cell therapies targeting various diseases, including diabetes, obesity, and muscular dystrophies. Current projects include the promising SMT-M01 for DMD and SMT-B01 focused on metabolic disorders. The company has successfully raised over $10 million to support their innovative initiatives.

Management Team Overview:

  • Micha Breakstone, PhD: CEO and Co-founder
  • Jonathan Rosenfeld, PhD: CTO and Co-founder
  • Carl Morris, PhD: Chief Scientific Officer
  • Kristy Brown, PhD: SVP Translational Development

About OmniaBio

OmniaBio Inc. is a leading cell and gene therapy contract development and manufacturing organization (CDMO) specializing in innovative regenerative medicine solutions. They have significant expertise in manufacturing immune cell-based therapies and advanced gene therapy applications. With ongoing improvements in their clinical production capabilities, OmniaBio is well-positioned to meet the growing demand for advanced therapeutic solutions worldwide.

Frequently Asked Questions

What is the purpose of Somite Therapeutics and OmniaBio's collaboration?

The collaboration aims to advance the development of SMT-M01, a cell replacement therapy targeting Duchenne muscular dystrophy.

How does AI play a role in this partnership?

Somite utilizes AI technology to enhance the discovery and optimization processes for cell therapy manufacturing, improving efficiency and effectiveness.

What is Duchenne muscular dystrophy?

DMD is a severe genetic disorder characterized by progressive muscle degeneration and weakness, with no known cure available.

When do the companies expect to start clinical trials?

The initial phase one/two clinical trials for SMT-M01 are anticipated to begin within 18 to 24 months.

What other programs does Somite Therapeutics focus on?

Besides SMT-M01 for DMD, Somite Therapeutics is also developing SMT-B01 aimed at metabolic disorders.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

K-Beauty Takes Front Stage at Target Beauty Studio

Updated Category News Views 5

Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...

Continue Reading
HTX's Strategic Moves in Pakistan: A Crypto Frontier

Updated Category News Views 6

Paving the Way: HTX's Journey in Pakistan Rolling into the Pakistan cryptocurrency scene isn't just a 'walk in the park' for HTX—it's more like traversing a new frontier with an open map. This isn’t some hit-and-run operation; HTX is strategizing for a long haul in one of the liveliest digital market arenas in South Asia. Gathering steam with community AMAs and an X...

Continue Reading
FJBio Boosts Antibody Discovery with Sapio AI

Updated Category News Views 5

In the sprawling world of antibody discovery, where every scrap of data can make or break the next big breakthrough, FairJourney Bio (FJBio) is pulling out all the stops. They've teamed up with Sapio Sciences to ditch the paperwork nightmares and usher in a new era of AI-driven efficiency. With operations stretching from Porto to Cambridge to sunny San Diego, they’re...

Continue Reading
Succession Planning in Turmoil: Only 42% Ready

Updated Category News Views 5

Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...

Continue Reading
The Chemical Industry and EPA: A Broken System?

Updated Category News Views 6

Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...

Continue Reading
FutureVault's AI Agents: Transforming Financial Workflows

Updated Category News Views 4

Revolutionizing Financial Operations: FutureVault's AI Approach In the dizzying whirlwind of financial services, the launch of FutureVault AI Agents is a game-changer for document management. This isn't some half-baked tool; it's a full-fledged overhaul of how compliance and operations should tick in the modern age. We've all seen it—a paper trail tangled across systems...

Continue Reading
Sean Trahan Joins Citrin Cooperman: New Tax Lead

Updated Category News Views 8

Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...

Continue Reading
AI-Driven Lumi Transforms Car Dealership Interactions

Updated Category News Views 8

Lumi: Changing the Car Buying Game Picture this: You're browsing for a new car, head filled with specifics like towing capacity, price points, and trim options. Usually, such queries would send you bouncing around the web, but Lectrium's Lumi promises to keep the questioning—and decision-making—right on the dealership's page. In a move set to shake up the game,...

Continue Reading
Dr. Desi Bartlett Teams Up with Glo for Perimenopause Focus

Updated Category News Views 4

Glo Taps Top Wellness Expert for Women's Health Initiative In an industry brimming with wellness voices, it's rare to find one that marries scholarly acumen with authentic, personal teaching. Yet, this is precisely what Dr. Desi Bartlett brings to the table as she partners with Glo to offer new fitness programming specifically targeting women facing perimenopause and...

Continue Reading
Anecdotes by Artists Brings Raw Scent Stories to Sephora

Updated Category News Views 3

When Maesa pulls back the curtain, they don't just crack it open—they fling it aside with flair. That's precisely what they're doing with their latest venture, Anecdotes by Artists, a fragrance brand that's taking its first bow exclusively at Sephora. It's not your average perfume launch; it's about the stories behind the scents and the artists who craft them. Unveiling...

Continue Reading

Top 5 Most Recently Viewed Articles

Amendments Approved by Baltic Horizon Fund Bondholders

Updated Category News Views 189

Key Amendments Approved for Baltic Horizon Fund Bonds Baltic Horizon Fund sought the approval of its bondholders for several amendments related to its EUR 42 million floating rate bonds set to mature in 2028. This written procedure occurred recently, allowing bondholders to engage in crucial decisions regarding the terms governing their investments. Voting Procedures and...

Continue Reading
Xnurta: Reinventing AI-Powered Advertising Solutions

Updated Category News Views 641

Xnurta: A New Era in AI-Powered Advertising Xnurta, previously known as Xmars, has been at the forefront of innovation in AI-driven ad management solutions. By rebranding, Xnurta not only changes its name but also signifies a transformative journey into the future of advertising alongside AI advancements. A Shift Towards Agentic AI This rebranding mirrors the exciting...

Continue Reading
Harrow Health's Bright Future: Innovations Driving Performance

Updated Category News Views 156

Harrow Health's Promising Innovations and Growth Strategy Harrow Health has recently caught the attention of financial analysts with an optimistic forecast from B. Riley. The financial services firm has raised its price target on Harrow Health (NASDAQ: HROW) shares to an impressive $73.00, significantly increasing it from the previous $50.00. Holding a Buy rating, B....

Continue Reading
F&G Annuities & Life Increases Dividend to $0.25 per Share

Updated Category News Views 132

F&G Annuities & Life Raises Common Stock Dividend Significantly F&G Annuities & Life, Inc. (NYSE: FG) has made an exciting announcement regarding their quarterly common stock dividend. The company revealed a remarkable 14% increase, moving from $0.22 to $0.25 per common share. This increase reflects the company’s strong performance and commitment to providing value to...

Continue Reading
MicroStrategy's Slight Recovery Sparks Hope for Bitcoin Growth

Updated Category News Views 107

MicroStrategy's Resilient Recovery After Market Setbacks MicroStrategy has recently made headlines with its remarkable recovery after a significant 16% drop in the market. This rebound raises an important question: Can a Bitcoin price surge to $100,000 continue to drive financial growth for companies invested in cryptocurrencies, especially MicroStrategy, a prominent...

Continue Reading